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Abstract: Ruthenium(II) complexes of formula [Ru(η
6
-arene)Cl
2
(PTA)] (RAPTA) are potential anticancer drugs with
notable antimetastatic and antiangiogenic activity, which are now pointing to clinical trials. Following the great
interest aroused by these compounds, a variety of RAPTA derivatives, obtained by chloride substitution and/or
containing functionalized arene ligands, and complexes resembling the RAPTA structure but bearing different
phosphorous ligands have been synthesized and evaluated for their anticancer activity. An overview of all of these
biologically relevant complexes will be given, with particular reference to the anticancer behaviour exhibited by
the compounds and the possible relationship with structural aspects.
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1. Ruthenium Compounds as
Possible Anticancer Drugs
The search for new and effective anti-
cancer drugs that overcome the limitations
of platinum-based chemotherapy currently
used in clinical treatments still represents
one of the most important objectives of
modern science.
[1]
In this respect, ruthe-
nium compounds play a major role, since
it is generally accepted that ruthenium
is relatively less toxic than platinum and
other heavy metals, and two ruthenium
compounds, i.e. KP1019 and NAMI-A,
reached phase II of clinical trials (Fig. 1).
[2]
It is believed that these Ru(iii) species
act as pro-drugs, in that they are con-
verted into the active Ru(ii) form by one
electron reduction in the tumour envi-
ronment.
[3]
This hypothesis has triggered
the investigation directly on a variety of
Ru(ii) compounds, and those based on
the Ru-arene scaffold have aroused major
attention.
[4]
In particular, [Ru(η
6
-arene)
Cl
2
(κP-PTA)] (RAPTA complexes), con-
taining the peculiar phosphine ligand
1,3,5-triaza-7-phosphatricyclo[3.3.1.1]de-
cane called PTA,
[5]
and [Ru(η
6
-biphenyl)
Cl(κ
2
N-NH
2
CH
2
CH
2
NH
2
)]X (X = PF
6
, Cl,
RM-175),
[6]
containing a bidentate ethyl-
ene-1,2-diamine ligand, have emerged as
among the most promising therapeutics,
showing great anticancer properties in vivo
(Fig. 1).
[7]
Following these successful dis-
coveries, many other derivatives have been
explored for their anticancer potential; in
this review, we will give a state of the art
of ruthenium arene compounds containing
phosphorous ligands that have been inves-
tigated.
2. Ruthenium Complexes with
a PTA Ligand
A vast series of compounds of general
formula [Ru(η
6
-arene)Cl
2
(κP-phosphine)]
can be easily obtained by addition of a
monodentate phosphine to the correspond-
ing precursor [Ru(η
6
-arene)Cl
2
]
2
, via sym-
metric cleavage of the dinuclear frame
(Scheme 1).
[8]
The resulting complexes are usually
air stable, even when containing air-sen-
sitive phosphines in normal conditions.
This procedure works well with 1,3,5-tri-
aza-7-phosphatricyclo[3.3.1.1]decane
(PTA) too, affording RAPTA complexes
developed by Dyson and co-workers,
[9]
that are generally non cytotoxic. However,
investigations on their antitumor efficacy
have been carried out on animal models:
in particular, [Ru(η
6
-p-cymene)Cl
2
(κP-
PTA)], RAPTA-C (Fig. 1), was shown to
be effective in reducing the growth of lung
metastases in mice affected by mammary
carcinoma in the absence of a correspond-
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Fig. 1. Most prominent ruthenium compounds investigated as possible anticancer drugs.
Scheme 1. General
synthesis of Ru(II) arene
phosphine complexes.
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with preferential binding to chromatin and
cancer-related proteins that may be respon-
sible for the observed antiangiogenic and
antimetastatic activities.
[12]
The mode of
action appears to be related to the hydro-
lysis of one Ru–Cl bond, this hydrolysis
being suppressed at high chloride concen-
trations.
[13]
A range of ruthenium arene-PTA com-
pounds have been prepared as variants of
the RAPTA, in order to evaluate the anti-
cancer potential. Even RAPTA analogues
based on Rh and Os have been synthe-
sized, and subsequent in vitro experiments
showed promising results on HT29 colon
carcinoma, A549 lung carcinoma, and
T47D breast carcinoma cells.
[14]
Complexes [Ru(η
6
-p-cymene)(κ
2
O-
C
2
O
4
)(PTA)] and [Ru(η
6
-p-cymene)
(κ
2
O-C
6
H
6
O
4
)(PTA)] (Fig. 2), containing
a bis-carboxylate ligand, are considerably
more soluble and more inert than their re-
spective RAPTA precursors. These com-
pounds, studied for their antiproliferative
activity against HT29 colon carcinoma,
A549 lung carcinoma, and T47D and
MCF7 breast carcinoma cell lines, were
found to exhibit a similar activity com-
pared to that of RAPTA-C, suggesting
their potential as possible antimetastatic
agents.
[15]
Ru
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Fig. 2. RAPTA-C derivatives with a bis-
carboxylate ligand.
Modification of the arene moiety was also
attempted in order to modulate the biolog-
ical behaviour of RAPTA compounds.
Hence, arene-linked diruthenium RAPTA
complexes were revealed to be significant-
ly more cytotoxic than the classical RAP-
TA series (Scheme 2a).
[16]
The introduction in the arene ring of
potential hydrogen bonding functionalities
was inspired by the fact that similar substi-
tution in titanocene-type drugs produced a
marked increase of cytotoxicity. However,
this approach to RAPTA compounds
(Scheme 2b) does not enhance their cy-
totoxicity towards cancer cell lines, in-
stead it leads to undesired toxicity towards
non-cancerous cells. This evidence was
explained on the basis of the reduced intra-
cellular uptake due to the functional group,
and possibly, easier release of hydrophilic
arenes from the Ru-PTA unit, compared
to the lipophilic ones.
[17]
However, using
arenes with pyrenyl-substituents
[18]
or
strongly electron withdrawing, fluorinated
groups (Scheme 2c) determines a consid-
erable increment of cytotoxicity towards
A2780 cell lines, compared to RAPTA C.
Given the electron-withdrawing nature of
the arene, the Ru-arene bond is expected to
be relatively weak, and this feature might
contribute to the enhanced cytotoxity.
Interestingly, the rate of hydrolysis in these
complexes was found to be favourable es-
pecially at low pH values, thus providing a
possible method of tumour targeting, con-
ing action against the primary tumour.
Moreover, RAPTA-C is able to reduce the
growth of ovarian and colorectal carci-
nomas, and a relatively low dose per day
(0.2 mg kg
–1
) is optimal against the A2780
ovarian carcinoma.
[10]
According to bio-
distribution studies, ruthenium is rapidly
released from the organs and the blood-
stream through excretion by the kidneys,
that is a desirable feature in view of possi-
ble clinical applications.
[11]
A multi-targeted mechanism of action
has been proposed for RAPTAcompounds,
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Scheme 2. RAPTA-type
compounds: a) arene
linked diruthenium
complexes; b) arene
functionalization with
hydrogen bonding
functionalities; c) arene
functionalization with
fluorinated groups.
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Scheme 3. Synthesis
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Berger reported [Ru(η
6
-arene)(κ
2
O-
acac
F
)(PTA)]
+
complexes (Scheme 4C),
containing fluorinated β-diketonate li-
gands (acac
F
), which showed a variable
antiproliferative activity against ovarian
and osteosarcoma cancer cells, but were
substantially inactive against non-malig-
nant keratinocytes.
[26]
The presence of
the PTA ligand confers to the complexes
higher inertness with respect to hydroly-
sis, compared to the corresponding neutral
compounds containing a chloride in place
of PTA. Indeed, stability studies in aque-
ous solution of [Ru(η
6
-arene)(κ
2
O-acac
F
)]
complexes evidenced the slow, partial re-
lease of the bidentate O,O-donor, besides
the typical, quick chloride elimination.
RAPTA complexes modified with
β-ketoamine ligands are still considerably
cytotoxic in vitro, exhibiting significant
sidering that low pH values are typical for
the tumour environment.
[19]
With the idea in mind that the combina-
tion of more than one pharmacophore may
enhance the anticancer potency of the drug,
the RAPTA-benzene framewas also deriva-
tised by an elegant synthetic procedure with
chloroambucil, i.e. an organic compound
used as an orally administered chemothera-
peutic (Scheme 3).
[20]
This strategy provid-
ed compounds with excellent in vitro an-
ticancer activity against cisplatin-resistant
cancer cells, superior to those of chloram-
bucil itself, RAPTA-T or a mixture of both.
A simple RAPTA-C variant
(RACAP-C), containing a phosphorus li-
gand closely resembling PTA, has been re-
cently reported by Peruzzini (Fig. 3); this
compound has higher antiproliferative ac-
tivity than the PTA analogue and displays
a reasonable degree of cancer cell selec-
tivity.
[21]
Ru
Cl
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N
N
N
RAPTA-C
Ru
Cl
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P
N
N
N
RACAP-C
Fig. 3. Comparative view of the structures of
RACAP-C and RAPTA-C.
Another possible change of the RAPTA
structural motif is the replacement of both
chloride ligands with bioactive, mono-an-
ionic β-diketonate moieties. Pettinari and
coworkers reported a series of such com-
pounds. Thus, [Ru(η
6
-arene)(κ
2
O-acac*)
(PTA)]
+
[arene = 4-C
6
H
4
(Me)(
i
Pr), cy-
mene; C
6
Me
6
, hexamethylbenzene], where
the bidentate oxygen donor (acac*) derives
from avobenzone, ortho-hydroxydibenzo-
ylmethane or acylpyrazolones, show mod-
erate cytotoxicity with comparable IC
50
values between A2780 and A2780R cell
lines, but scarce selectivity with respect
to non-tumorous cells (Scheme 4A).
[22]
Of most interest is the use of curcumin as
β-diketonate precursor; in fact, curcumin
possesses notable properties, such as an-
tioxidant, antiproliferative, anticancer,
and antiangiogenic, and its efficacy in the
treatment of a number of diseases has been
ascertained.
[23]
The ruthenium-curcum-
in compounds (Scheme 4B) showed low
IC
50
values against tumoral cells, while
maintaining an excellent selectivity with
respect to non-cancerous human embry-
onic kidney cells.
[24]
In these complexes,
the PTA ligand is believed to contribute to
the pharmacological efficacy in a signifi-
cant manner, and remarkable proteasome
inhibition activity has been ascertained for
related neutral species.
[25]
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Scheme 4. Examples of RAPTA derivatives with β-diketonate (A–C) and β-ketoiminate (D) ligands
tested for their anticancer activity.
Scheme 5. Ruthenium(II) arene compounds with stereogenic trialkylphosphines.
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tin (Fig. 4a). All of these complexes are
able to interact with transferrin and DNA,
which can be viewed as possible drug tar-
gets.
[29]
Aminophosphines complexes with a
β-diketonate ligand, i.e. [Ru(η
6
-p-cymene)
(O,O-acac)(PPh
2
R)] (R = 2-pyridine or
imidazole), exhibit moderate to good cyto-
toxic behaviour in vitro against the human
cancer cell lines MCF-7 (breast cancer)
and CAPAN-1 (pancreatic cancer), see
Fig. 4b.
[30]
By modulating the nature of
the R group, it is possible to tune the ac-
tivity, the best results being achieved with
the pyridine species. These are supposed to
quickly release the β-diketonate moiety in
aqueous environment, possibly due to the
donor ability of the pyridine group activat-
ing the complex.
The introduction of a triphenylphos-
phine ligand usually enhances the hydro-
phobicity of the resulting ruthenium arene
complex, thus leading to higher levels of
cytotoxicity in vitro. However, this can re-
sult in decrease of selectivity on the other
hand, as has been ascertained by replacing
one chloride with triphenylphosphine in
RAPTA-C and RAPTA-OH complexes.
[31]
Cationic complexes [Ru(η
6
-p-cymene)
(py)Cl(PPh
3
)]
+
, bearing a pyridine (py) li-
gand (Fig. 5), showed IC
50
values against
human leukaemia tumour cell line com-
parable to that obtained with cisplatin. It
has been demonstrated that the ruthenium
triphenylphosphine complexes are able
to bind DNA and distort its secondary
and tertiary structure, whereas analogous
complexes lacking of PPh
3
bind DNA in a
covalent manner only.
[32]
Arene ruthenium
complexes with S-functionalized phos-
phine ligands were revealed to be potently
cytotoxic (cell lines 518A2, 8505C, A253,
MCF-7, SW480), with higher antiprolif-
erative activity with respect to the parent
neutral complexes (Fig. 5). A correlation
has been found between the lengths of the
methylene spacers and the cytotoxic activ-
ity (MCF-7, SW480 cells), i.e. the longer
the spacer the higher the in vitro activity.
[33]
In general, the highest levels of cyto-
toxity were reached with the sulphide-con-
taining ligands. Hartinger recently found
that the incorporation of PPh
3
within
Ru(ii) arene complexes of 3-hydroxy-
4(1H)-pyr(id)one ligands (Fig. 6) resulted
in a dramatic increase in the antiprolifer-
ative activity against human colorectal
(HCT116), cervical (SiHa), non-small
cell lung (NCI-H460), and colon (SW480)
carcinoma cell lines.
[34]
A similar effect
was ascertained for letrozole-ruthenium
analogues.
[35]
Alternatively to the use of
β-diketonate ligands (see above), that of
(ortho-hydroxyphenyl)diphenyl phosphine
may be taken into consideration: the ionic
compound [Ru(η
6
-p-cymene){κ
2
P,O-PPh
2
(2-C
6
H
4
O)}(PTA)]Cl is weakly cytotoxic
cytotoxicity even against cisplatin resist-
ant ovarian A2780 cancer cells (Scheme
4D); the anticancer behaviour of these
complexes seems to be finely tuneable by
slight structural modifications on the β-ke-
toamine fragment.
[27]
3. Ruthenium Complexes with
Other Phosphine Ligands
Avariety of complexes obtained by for-
mal replacement of PTAwith an alternative
P-ligand have been prepared and evaluated
as anticancer agents. Some complexes of
general formula [Ru(η
6
-p-cymene)Cl
2
(P)],
containing a stereogenic trialkylphosphine
ligand with a silicon side-group (P), were
evaluated against human leukaemia cancer
cells (HL-60), exhibiting IC
50
values in the
same order of magnitude as cisplatin.
[28]
An analogous complex in which one of the
P-substituents is tethered to the arene ring
through a short spacer, was found to be
considerably less cytotoxic (Scheme 5).
Similarly, complexes with ami-
nomethylphosphanes, i.e. [(η
6
-p-cymene)
RuCl
2
(PPh
2
R)], were studied for their
cytotoxicity against the A549 (human
lung adenocarcinoma) and MCF7 (human
breast adenocarcinoma) cell lines, show-
ing activities comparable to that of cispla-
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B
Fig. 4. Ru(II) p-cymene
compounds with:
a) aminomethyl-
phosphines;
b) aminophosphines.
Fig. 6. Cationic Ru(II)
arene complexes with
mono- or bidentate
triphenylphosphine
ligands.
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Fig. 5. Ru(II) p-cymene complexes with pyridine ligands or chelating P,S ligands.
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possible cancer cell selectivity supplied by
the carbohydrate moiety (Scheme 7).
[40]
Indeed the resulting complexes showed a
certain degree of selectivity against several
cancer cell lines compared to the non-tu-
morigenic cell line. The best performance
was achieved by increasing the lipophilici-
tyof the carbohydrate-mimickinggroup,
[41]
while the introduction of a bis-carboxylate
ligand in place of two halides led to a de-
crease of the in vitro anticancer activity.
[42]
The phosphine PPh
2
(4-C
6
H
4
CO
2
H) is
relatively air stable and it has been used
to obtain a series of phosphine ligands
derivatised with bioactive groups, more
precisely ethacrynic acid,
[43]
indometha-
cin and diclofenac.
[44]
The latter two are
anti-inflammatory drugs, whereas eth-
acrynic acid is an inhibitor of GSTs en-
zymes, these enzymes being involved in
cell resistance mechanisms. The resulting
[Ru(η
6
-p-cymene)Cl
2
(P)] complexes dis-
play moderate to good activity towards
A2780 and A2780cisR cancer cells, with
some difference in the activity compared to
the respective phosphine ligands (Fig. 8).
However, none of these complexes showed
selectivity between the cancer cells and the
non tumorigenic cell line.
The phosphine PPh
2
(4-C
6
H
4
OH)
and its ester derivatives are significant-
ly less air tolerant compared to PPh
2
(4-
C
6
H
4
CO
2
H). Notwithstanding, the former
can be employed as a convenient linker of
bioactive carboxylic acids to the ruthenium
moiety, according to a general method.
[45]
Hence, the complex [(η
6
-p-cymene)
RuCl
2
(κP-PPh
2
(4-C
6
H
4
OH))]
[46]
has been
coupled with a series of bioactive carbox-
ylic acids via direct esterification of the hy-
droxyl group belonging to the coordinated
phosphine ligand (Fig. 9). This procedure
negates the need for protecting strategies,
since the chloride ligands are not affect-
ed by the functionalization reactions. The
resulting complexes, in general, display
IC
50
values in the range 9 to 50 mM to-
wards the ovarian cancer cells A2780 and
A2780cisR, but no selectivity compared
4. Inclusion of Bioactive Molecules
in Ruthenium Arene Phosphine
Complexes
The inclusion of bioactive molecules
within metal complexes represents a com-
mon strategy to enhance and tune the bi-
ological behaviour of potential drugs. In
this respect, a variety of phosphine ligands
have been used to tether various bioactive
fragments to the ruthenium(ii) arene frame.
Complexes resembling the structure of
RAPTA-C and containing 3,5,6-bicyclo-
phosphites of α-d-glucofuranoside were
designed in order to combine the antican-
cer activity of the Ru(ii) frame with the
(IC
50
= 138 μM) on A2780 ovarian cancer
cells,moreover it is inert in aqueous solution
and with respect to possible cellular targets,
therefore it is assumed to act through non
covalent interactions (Fig. 6).
[36]
The triphenylphosphine moiety can
also be employed as a versatile scaffold
for tethering specific functionalities to
the ruthenium centre. For instance, deri-
vatization of a triphenylphosphine with
BODIPY gave access to highly fluores-
cent ruthenium arene complexes (Scheme
6). Monitoring the drug uptake in cancer
cells in vitro, it has been possible to estab-
lish the preferential accumulation of the
Ru-species in the cell membranes, without
being able to reach the nuclei.
[37]
An interesting approach to supply se-
lectivity to the ruthenium drug consists
in replacing the PTA ligand with a per-
fluorinated phosphine, i.e. a phosphine
bearing fluourous alkyl chains, whose
solubility is strictly dependant on the tem-
perature.
[38]
For instance, the solubility
of P(C
2
H
4
C
8
F
17
)
3
in octane increases by
600 times in the temperature range −20
to 80 °C.
[39]
As a further modification, the
amphiphilic phosphine PTA ligand can be
added in place of a chloride ligand (Fig. 7).
Up to four-fold increase in water solubil-
ity of some of the ruthenium derivatives
has been detected at 42 °C, making such
compounds suitable candidates for thermal
chemotherapy.
Scheme 6. Functionalization with BODIPY at a triphenylphosphine ligand affording fluorescent
complexes.
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Scheme 7. Introduction
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to non-tumorigenic cells. The cytotoxicity
data clearly evidence a synergic contribu-
tion of the Ru-arene frame and the bioac-
tive group to the antiproliferative potential
of the overall complex.
5. Heterobimetallic Complexes
Phosphine units have been used to con-
nect transition metal frames with potential
anticancer activity to the Ru(ii) arene skel-
eton, leading to heteronuclear compounds.
This approach has allowed the combina-
tion with the titanocene dichloride moiety,
aimed to conjugate the anticancer proper-
ties of the respective titanium and ruthe-
nium species (Fig. 10).
[47]
Interestingly,
the obtained hetero-dinuclear compounds
were found to be considerably more active
against theA2780 cancer cell line than their
parent mononuclear Ti and Ru precursors,
and even more cytotoxic than cisplatin in
the corresponding resistant cell line.
[48]
The RuCl
2
(arene) fragment has also
been connected to a ferrocenyl diphenyl
phosphine, the resulting ruthenium-ferro-
cene conjugate showing moderate to good
in vitro anticancer activity (A2780 and
A2780cisR cell lines).
[49]
6. Conclusions
Ruthenium(ii) complexes of the
RAPTA series, [Ru(η
6
-arene)Cl
2
(PTA)],
are promising anticancer agents, exhibit-
ing low cytotoxicity in vitro but notable an-
timetastatic and antiangiogenic activity in
vivo. A variety of structural modifications
have been performed in order to modulate
the activity of the complexes, including
functionalization of the arene ring, intro-
duction of bidentate donors in the place
of the chloride ligands, diversification of
the phosphorus ligand, introduction of
bioactive groups and combination with
heterometallic fragments. This plethora of
structural possibilities provide several op-
portunities in terms of solubility, biologi-
cal behaviour, antiproliferative activity in
vivo and, possibly, in vivo performance of
the potential drugs.A development and ex-
tensive biological investigation
[50]
of these
systems could lead to fundamental steps in
the direction of fighting cancer.
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